Autus Valve Pivotal Study
Key facts
- Who runs it
- Edwards Lifesciences
- Where
- Ann Arbor, Atlanta, Aurora, Boston, Chicago, Columbus, Durham, Los Angeles, New York, Philadelphia, Salt Lake City, and Seattle, United StatesSee the 12 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 62 people enrolled
- Started
- 5 Feb 2024
- Expected to end
- 5 Feb 2036
- Type of study
- Interventional
- Treatments tested
- Pulmonary Valve Replacement Surgery
- Record updated
- 20 October 2026
Who can take part
- Age
- 18 months to 16 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Candidates must meet all of the following inclusion criteria to be considered for enrollment in this study
- Age 18 months to 16 years
- Male or female
- Subject has a native or repaired right ventricular outflow tract
- Subject has been recommended for surgical pulmonary valve replacement by treating clinical team (cardiologist and cardiac surgeon)
- Subject has at least one of the following echocardiographic findings:; Severe pulmonary stenosis (defined as RV to PA peak instantaneous gradient ≥60 mmHg); Moderate or greater pulmonary regurgitation; Moderate or greater pulmonary stenosis plus moderate or greater pulmonary regurgitation
- Subject's body size is suitable for implantation of a study device ranging from 12.7 to 22 mm (internal diameter)
- Subject and parent/legal representative, where appropriate, are willing to provide informed written consent
- Subject and parent/legal representative, where appropriate, and treating physician agree that the subject will return for, and comply with, all required study assessments and follow-up visits
Who cannot take part
- Positive pregnancy test prior to valve implant procedure in female subjects who have had their first menses
- Subject is participating in an investigational study of a new drug, biologic or device at the time of study screening
- Candidates will be excluded from the study if any of the following conditions are met:
- Subject has pulmonary arterial hypertension (defined as mean PA pressure ≥25 mmHg)
- Subject has an active infection requiring current systemic antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics)
- Subject has active endocarditis or a history of infective endocarditis
- Subject has a known hypersensitivity to anticoagulants and antiplatelet drugs
- Subject has a known autoimmune disease or receives immunosuppressant and/or immunostimulant drugs that the Investigator or Eligibility Screening Committee (ESC) believes may negatively affect study outcomes
- Subject needs emergency cardiac or vascular surgery or intervention
- Subject has renal insufficiency as determined by a serum creatinine (S-Cr) level ≥2.5 mg/dL within 60 days prior to the Screening Visit, or has end-stage renal disease
- Subject has leukopenia (defined as a white blood cell (WBC) count <3.5 x 103/µL)
- Subject has acute or chronic anemia (defined as hemoglobin (Hgb) <10.0 g/dl or 6 mmol/L)
- Subject has thrombocytopenia (defined as platelet count <50 x 103/µL
- Subject requires valve replacement in a non-pulmonary position
- Subject has a prosthetic valve at other valve position or will need a prosthetic valve at other valve position (i.e., anticipate additional valve replacements needed within 3 years)
- Subject has pulmonary atresia and major aortopulmonary collaterals
- Subject has significant peripheral pulmonary artery stenosis
- Subject has, in the opinion of the Investigator, a life expectancy of less than 5 years
- Subject or parent/legal representative refuses blood transfusions
- Subject has medical, social or psychosocial factors that, in the opinion of the Investigator or ESC, could impact safety or compliance with study procedures
Where in United States
- University of Michigan/Mott Children's HospitalAnn Arbor, United States
- Children's Healthcare of AtlantaAtlanta, United States
- Children's Hospital ColoradoAurora, United States
- Boston Children's HospitalBoston, United States
- Ann and Robert H. Lurie Children's Hospital of ChicagoChicago, United States
- Nationwide Children's HospitalColumbus, United States
- Duke UniversityDurham, United States
- Children's Hospital Los AngelesLos Angeles, United States
- Columbia University Irving Medical Center/New York Presbyterian Morgan Stanley Children's HospitalNew York, United States
- Children's Hospital of PhiladelphiaPhiladelphia, United States
- University of Utah - Intermountain Primary Children's HospitalSalt Lake City, United States
- Seattle Children's HospitalSeattle, United States
About the trial
What the trial wants to find out
Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 months, and annually through 10 years.
Read full original descriptionShow less
The Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject. In subjects who undergo a post-implant valve expansion, follow-up will continue for a minimum of 1 year after the post-implant valve expansion procedure.
The group in the trial
- Autus Valve ArmTreatment being tested
Pulmonary Valve Replacement Surgery with the Autus Valve
Treatment: Pulmonary Valve Replacement Surgery
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Autus Size-Adjustable Valve for Surgical Pulmonary Valve Replacement Pivotal Study
- Record updated
- 20 October 2026